Drugmakers Must Face FTC’s AndroGel Antitrust Suit

Law360 (June 14, 2018, 9:35 PM EDT) -- A Georgia federal judge largely refused Thursday to let a group of pharmaceutical companies out of a nearly decade-old antitrust multidistrict litigation from the Federal Trade Commission and private parties alleging that they conspired to keep generic competitors for testosterone drug AndroGel off the market.

Brandmaker AbbVie Products LLC and generics companies Actavis Inc. and Par Pharmaceutical Companies Inc. and Paddock Holdings LLC cannot dodge allegations of an antitrust conspiracy to delay generic competition to AbbVie’s AndroGel, said U.S. District Judge Thomas W. Thrash Jr. He held further that the FTC and private plaintiffs — divided into retailers and direct drug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS